Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 5
2003 8
2004 10
2005 13
2006 13
2007 25
2008 33
2009 77
2010 113
2011 130
2012 165
2013 185
2014 261
2015 340
2016 403
2017 430
2018 424
2019 447
2020 428
2021 458
2022 415
2023 438
2024 259

Text availability

Article attribute

Article type

Publication date

Search Results

4,467 results

Results by year

Filters applied: . Clear all
Page 1
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team; Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Armstrong MJ, et al. Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20. Lancet. 2016. PMID: 26608256 Free article. Clinical Trial.
The trial was designed using A'Hern's single-group method, which required eight (38%) of 21 successes in the liraglutide group for the effect of liraglutide to be considered clinically significant. ...Two (9%) of 23 patients in the liraglutide group versus ei …
The trial was designed using A'Hern's single-group method, which required eight (38%) of 21 successes in the liraglutide group for th …
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. O'Neil PM, et al. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Lancet. 2018. PMID: 30122305 Clinical Trial.
Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss. METHODS: We did a randomised, double-blind, placebo and active controlled, multicentre, dose-r …
Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutid …
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Møller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Lundgren JR, et al. N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198. N Engl J Med. 2021. PMID: 33951361 Clinical Trial.
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide …
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity …
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Wadden TA, et al. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726. Obesity (Silver Spring). 2020. PMID: 32090517 Free PMC article. Clinical Trial.
The present multisite study provides the first evaluation, in primary care, of the effect of the Centers for Medicare and Medicaid Services-based IBT benefit, delivered alone (with placebo) or in combination with liraglutide 3.0 mg. METHODS: The Satiety and Clinical Adipos …
The present multisite study provides the first evaluation, in primary care, of the effect of the Centers for Medicare and Medicaid Services- …
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Jacobsen LV, et al. Clin Pharmacokinet. 2016 Jun;55(6):657-72. doi: 10.1007/s40262-015-0343-6. Clin Pharmacokinet. 2016. PMID: 26597252 Free PMC article. Review.
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and greatly protracted action. ...The pharmacokinetic and pharmacodynamic properties of liraglutide make it an important treatment option fo …
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and gre …
Liraglutide and obesity: a review of the data so far.
Ladenheim EE. Ladenheim EE. Drug Des Devel Ther. 2015 Mar 30;9:1867-75. doi: 10.2147/DDDT.S58459. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25848222 Free PMC article. Review.
Recent research has suggested that long-acting analogs of the gut hormone, glucagon-like peptide 1 (GLP-1), may have potential as an antiobesity treatment. The GLP-1 receptor agonist, liraglutide (trade name Saxenda), was recently approved by the US Food and Drug Administr …
Recent research has suggested that long-acting analogs of the gut hormone, glucagon-like peptide 1 (GLP-1), may have potential as an antiobe …
Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization.
Li SL, Wang ZM, Xu C, Che FH, Hu XF, Cao R, Xie YN, Qiu Y, Shi HB, Liu B, Dai C, Yang J. Li SL, et al. Front Immunol. 2022 Apr 5;13:869050. doi: 10.3389/fimmu.2022.869050. eCollection 2022. Front Immunol. 2022. PMID: 35450076 Free PMC article.
This study aimed to investigate whether liraglutide can protect the liver from IRI and determine the possible underlying mechanisms. ...However, the protective effects of liraglutide on hepatic IRI were partly diminished in GLP-1 receptor-knockout (GLP-1R(-/-)) mice …
This study aimed to investigate whether liraglutide can protect the liver from IRI and determine the possible underlying mechanisms. …
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Tamborlane WV, et al. N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28. N Engl J Med. 2019. PMID: 31034184 Clinical Trial.
However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. ...The fasting plasma glucose level had de …
However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or …
Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice.
Song JX, An JR, Chen Q, Yang XY, Jia CL, Xu S, Zhao YS, Ji ES. Song JX, et al. Bioengineered. 2022 Apr;13(4):8334-8348. doi: 10.1080/21655979.2022.2051858. Bioengineered. 2022. PMID: 35311455 Free PMC article.
First, liraglutide decreased serum AST and ALT levels, and suppressed liver fibrosis in db/db mice. ...Furthermore, liraglutide attenuated iron deposition by decreasing TfR1 expression and increasing FPN1 expression. ...
First, liraglutide decreased serum AST and ALT levels, and suppressed liver fibrosis in db/db mice. ...Furthermore, liraglutide …
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Pratley R, et al. Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Lancet. 2019. PMID: 31186120 Clinical Trial.
The primary endpoint was change from baseline to week 26 in HbA(1c) (oral semaglutide superiority vs placebo and non-inferiority [margin: 0.4%] and superiority vs subcutaneous liraglutide) and the confirmatory secondary endpoint was change from baseline to week 26 in bodyw …
The primary endpoint was change from baseline to week 26 in HbA(1c) (oral semaglutide superiority vs placebo and non-inferiority [margin: 0. …
4,467 results

Searches related to "liraglutide"